Welcome to CSNpharm! For Research Use Only!
c-Myc
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN25655 | Mycro 3 | 944547-46-0 | Mycro3 is a small-molecule inhibitor of Myc-Max dimerization. The average residual tumor of Pdx1-cre/KRAS* mice after Mycro3 treatment (100mg/kg, orally, daily for 2 months) is approximately 30%. |
| CSN27224 | MYCMI-6 | 681282-09-7 | MYCMI-6 (NSC354961) is a potent and selective endogenous MYC:MAX protein interactions inhibitor. MYCMI-6 blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with a Kd of 1.6 μM. MYCMI-6 inhibits tumor cell growth in a MYC-dependent manner (IC50<0.5 μM). MYCMI-6 is not cytotoxic to normal human cells. MYCMI-6 induces apoptosis . |
| CSN27192 | MYCi975 | 2289691-01-4 | MYCi975 improved analog of MYCi361 which is a MYC inhibitor. It showed better tolerability compared with MYCi361. |
| CSN27191 | MYCi361 | 2289690-31-7 | MYCi361 is a MYC inhibitor with Kd value of 3.2μM. It engages MYC inside cells, disrupts MYC/MAX dimers, and impairs MYC-driven gene expression. MYCi361 suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. |
| CSN21249 | ML327 | 1883510-31-3 | ML327 is a blocker of MYC which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition EMT |
| CSN18344 | KJ Pyr 9 | 581073-80-5 | KJ Pyr 9 is a small-molecule inhibitor of MYC The Kd of KJ Pyr 9 for MYC in vitro is 6510 nM as determined by backscattering interferometry |
| CSN20454 | 10074-G5 | 413611-93-5 | 10074-G5 is a c-Myc Max interaction inhibitor. |
| CSN12467 | 10058-F4 | 403811-55-2 | 10058-F4 is a cell-permeable thiazolidinone that specificallly inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression and induces cell-cycle arrest and apoptosis. |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
